Richard Thomas Menziuso - 01 Oct 2026 Form 4 Insider Report for Altimmune, Inc. (ALT)

Reporting relationship: Principal Accounting Officer
Issuer ticker: ALT
Reported as of: 01 Oct 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 02 Oct 2026, 16:17:53 UTC
Source filing: View source filing
Reporting owner signature: /s/ Gregory Weaver, as Attorney-in-Fact

Key filing fact

Richard Thomas Menziuso filed Form 4 for Altimmune, Inc. (ALT) on 02 Oct 2026.

Key facts

This page summarizes Richard Thomas Menziuso's Form 4 filing for Altimmune, Inc. (ALT).
2 reported transactions and 2 derivative rows are listed below.
Accepted by SEC: 02 Oct 2026, 16:17.

Change

No earlier filing in this sequence is available for direct comparison.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0002156820 Primary reporting owner

MENZIUSO RICHARD THOMAS

Relationship: Principal Accounting Officer
Address: 910 CLOPPER ROAD, SUITE 201S, GAITHERSBURG
Signature: /s/ Gregory Weaver, as Attorney-in-Fact
Signature date: 02 Oct 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

ALT transaction Derivative

Stock Options (option to buy)

Award

Transaction value
Shares: +84,546
Change %
Price: $0.000000^*
Shares after: 84,546
Date: 01 Oct 2026
Ownership: Direct
Underlying class: Common Stock, par value $0.0001
Underlying amount: 84,546
Exercise price: $2.76
Footnotes: F1

ALT transaction Derivative

Restricted Stock Units

Award

Transaction value
Shares: +36,234
Change %
Price: $0.000000^*
Shares after: 36,234
Date: 01 Oct 2026
Ownership: Direct
Underlying class: Common Stock, par value $0.0001
Underlying amount: 36,234
Exercise price
Footnotes: F2, F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

The shares underlying the option become vested and exercisable over four (4) years with 25% of the shares vesting on October 1, 2027, with the remainder vesting in equal monthly installments for the following thirty-six (36) months, subject to the reporting person's continued service on each applicable vesting date.

Footnote F2

Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Common Stock, par value $0.0001, when vested.

Footnote F3

The RSUs become vested over four (4) years with 25% of the shares vesting on October 1, 2027, with the remainder vesting in equal annual installments for the following three (3) years, subject to the reporting person's continued service through the applicable vesting date, and have no expiration dat.